FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a humanized antibody or antigen-binding fragment thereof, which neutralizes human VEGF, as well as to compositions and a set containing it. Also disclosed is an isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof, as well as a vector and a host cell containing it. The invention also relates to a method for inhibiting human VEGF mediated endothelial cell proliferation and vascular permeability in a patient with a human VEGF mediated disease using the aforementioned antibody.
EFFECT: invention can be effectively used for treatment of a disease mediated by human VEGF.
32 cl, 15 dwg, 12 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
